The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global ADHD Medications Market Research Report 2024
Synopsis
ADHD medications can help reduce symptoms of hyperactivity, inattentiveness, and impulsivity in children and adults with attention deficit hyperactivity disorder (ADHD), formerly known as ADD.
The global ADHD Medications market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for ADHD Medications, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding ADHD Medications.
Report Scope
The ADHD Medications market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global ADHD Medications market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the ADHD Medications companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amneal Pharmaceuticals
Eli Lilly and Co.
Johnson and Johnson Services
NEOS Therapeutic
Takeda Pharmaceutical
Pfizer
Lupin
Shire
Mallinckrodt
Segment by Type
Stimulant
Non-stimulant
Segment by Application
Adult
Children
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of ADHD Medications companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
ADHD medications can help reduce symptoms of hyperactivity, inattentiveness, and impulsivity in children and adults with attention deficit hyperactivity disorder (ADHD), formerly known as ADD.
The global ADHD Medications market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for ADHD Medications, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding ADHD Medications.
Report Scope
The ADHD Medications market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global ADHD Medications market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the ADHD Medications companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amneal Pharmaceuticals
Eli Lilly and Co.
Johnson and Johnson Services
NEOS Therapeutic
Takeda Pharmaceutical
Pfizer
Lupin
Shire
Mallinckrodt
Segment by Type
Stimulant
Non-stimulant
Segment by Application
Adult
Children
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of ADHD Medications companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global ADHD Medications Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Stimulant
1.2.3 Non-stimulant
1.3 Market by Application
1.3.1 Global ADHD Medications Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Adult
1.3.3 Children
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global ADHD Medications Market Perspective (2019-2030)
2.2 ADHD Medications Growth Trends by Region
2.2.1 Global ADHD Medications Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 ADHD Medications Historic Market Size by Region (2019-2024)
2.2.3 ADHD Medications Forecasted Market Size by Region (2025-2030)
2.3 ADHD Medications Market Dynamics
2.3.1 ADHD Medications Industry Trends
2.3.2 ADHD Medications Market Drivers
2.3.3 ADHD Medications Market Challenges
2.3.4 ADHD Medications Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top ADHD Medications Players by Revenue
3.1.1 Global Top ADHD Medications Players by Revenue (2019-2024)
3.1.2 Global ADHD Medications Revenue Market Share by Players (2019-2024)
3.2 Global ADHD Medications Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by ADHD Medications Revenue
3.4 Global ADHD Medications Market Concentration Ratio
3.4.1 Global ADHD Medications Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by ADHD Medications Revenue in 2023
3.5 ADHD Medications Key Players Head office and Area Served
3.6 Key Players ADHD Medications Product Solution and Service
3.7 Date of Enter into ADHD Medications Market
3.8 Mergers & Acquisitions, Expansion Plans
4 ADHD Medications Breakdown Data by Type
4.1 Global ADHD Medications Historic Market Size by Type (2019-2024)
4.2 Global ADHD Medications Forecasted Market Size by Type (2025-2030)
5 ADHD Medications Breakdown Data by Application
5.1 Global ADHD Medications Historic Market Size by Application (2019-2024)
5.2 Global ADHD Medications Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America ADHD Medications Market Size (2019-2030)
6.2 North America ADHD Medications Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America ADHD Medications Market Size by Country (2019-2024)
6.4 North America ADHD Medications Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe ADHD Medications Market Size (2019-2030)
7.2 Europe ADHD Medications Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe ADHD Medications Market Size by Country (2019-2024)
7.4 Europe ADHD Medications Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific ADHD Medications Market Size (2019-2030)
8.2 Asia-Pacific ADHD Medications Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific ADHD Medications Market Size by Region (2019-2024)
8.4 Asia-Pacific ADHD Medications Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America ADHD Medications Market Size (2019-2030)
9.2 Latin America ADHD Medications Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America ADHD Medications Market Size by Country (2019-2024)
9.4 Latin America ADHD Medications Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa ADHD Medications Market Size (2019-2030)
10.2 Middle East & Africa ADHD Medications Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa ADHD Medications Market Size by Country (2019-2024)
10.4 Middle East & Africa ADHD Medications Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amneal Pharmaceuticals
11.1.1 Amneal Pharmaceuticals Company Detail
11.1.2 Amneal Pharmaceuticals Business Overview
11.1.3 Amneal Pharmaceuticals ADHD Medications Introduction
11.1.4 Amneal Pharmaceuticals Revenue in ADHD Medications Business (2019-2024)
11.1.5 Amneal Pharmaceuticals Recent Development
11.2 Eli Lilly and Co.
11.2.1 Eli Lilly and Co. Company Detail
11.2.2 Eli Lilly and Co. Business Overview
11.2.3 Eli Lilly and Co. ADHD Medications Introduction
11.2.4 Eli Lilly and Co. Revenue in ADHD Medications Business (2019-2024)
11.2.5 Eli Lilly and Co. Recent Development
11.3 Johnson and Johnson Services
11.3.1 Johnson and Johnson Services Company Detail
11.3.2 Johnson and Johnson Services Business Overview
11.3.3 Johnson and Johnson Services ADHD Medications Introduction
11.3.4 Johnson and Johnson Services Revenue in ADHD Medications Business (2019-2024)
11.3.5 Johnson and Johnson Services Recent Development
11.4 NEOS Therapeutic
11.4.1 NEOS Therapeutic Company Detail
11.4.2 NEOS Therapeutic Business Overview
11.4.3 NEOS Therapeutic ADHD Medications Introduction
11.4.4 NEOS Therapeutic Revenue in ADHD Medications Business (2019-2024)
11.4.5 NEOS Therapeutic Recent Development
11.5 Takeda Pharmaceutical
11.5.1 Takeda Pharmaceutical Company Detail
11.5.2 Takeda Pharmaceutical Business Overview
11.5.3 Takeda Pharmaceutical ADHD Medications Introduction
11.5.4 Takeda Pharmaceutical Revenue in ADHD Medications Business (2019-2024)
11.5.5 Takeda Pharmaceutical Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer ADHD Medications Introduction
11.6.4 Pfizer Revenue in ADHD Medications Business (2019-2024)
11.6.5 Pfizer Recent Development
11.7 Lupin
11.7.1 Lupin Company Detail
11.7.2 Lupin Business Overview
11.7.3 Lupin ADHD Medications Introduction
11.7.4 Lupin Revenue in ADHD Medications Business (2019-2024)
11.7.5 Lupin Recent Development
11.8 Shire
11.8.1 Shire Company Detail
11.8.2 Shire Business Overview
11.8.3 Shire ADHD Medications Introduction
11.8.4 Shire Revenue in ADHD Medications Business (2019-2024)
11.8.5 Shire Recent Development
11.9 Mallinckrodt
11.9.1 Mallinckrodt Company Detail
11.9.2 Mallinckrodt Business Overview
11.9.3 Mallinckrodt ADHD Medications Introduction
11.9.4 Mallinckrodt Revenue in ADHD Medications Business (2019-2024)
11.9.5 Mallinckrodt Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
